Volition RX announced interim results from its asymptomatic colorectal cancer frontline screening study, finding it successfully detected stage 1 CRC 80 percent of the time.
Here's what you should know:
1. Researchers sent 680 patients from the Danish National CRC Screening Program three Elisa assays to screen for CRC. They found the test detected 80 percent of stage 1 CRC cases and 66 percent of high-risk adenomas at a 78 percent specificity.
2. Volition is also participating in a CRC screening study in the U.S., through a collaboration with the National Cancer Institute. The study is screening 13,500 subjects with results expected by 2020. Volition plans to use its European and U.S. data to refine test performance and submit the data to the FDA for approval.
3. Volition anticipates the final assay panel for its U.S. frontline test will be defined in the next 18 months.
Volition CEO Cameron Reynolds said, "After seven years of hard work, we are happy to announce these excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer. Using only a small panel of three assays and considering certain limited patient variables, [this] data demonstrate that we can identify early stage and pre-cancerous adenomas at a high level of accuracy in an asymptomatic screening environment."